Expand LXRX Menu
LXRX MENU

LXRX Latest Press Releases

-- November 26, 2024 --

Lexicon Announces Completion of Enrollment in Phase 2B PROGRESS Study of LX9211 in Diabetic Peripheral Neuropathic Pain (DPNP) Globe Newswire 8:00 AM

-- November 25, 2024 --

Lexicon Pharmaceuticals to Participate in December Investor Conferences Globe Newswire 4:15 PM

-- November 22, 2024 --

Lexicon to Reposition as Clinical Development-Focused Company Following Regulatory Update From FDA Globe Newswire 7:32 AM

-- November 20, 2024 --

Lexicon Appoints Ivan H. Cheung to Board of Directors Globe Newswire 4:10 PM

-- November 14, 2024 --

Post-Hoc Analysis Demonstrating Sotagliflozin Benefits Across Broad Spectrum of Heart Failure Patient Populations is Among Four Lexicon-Supported Presentations at the American Heart Association's (AHA) Sessions 2024 in Chicago Globe Newswire 8:00 AM

-- November 12, 2024 --

Lexicon Pharmaceuticals Reports Third Quarter 2024 Financial Results and Provides Business Update Globe Newswire 4:05 PM

-- November 6, 2024 --

Lexicon Pharmaceuticals to Participate in the Jefferies London Global Healthcare Conference Globe Newswire 8:00 AM

-- November 5, 2024 --

Published Data in Journal of American Society of Nephrology Highlights Findings on Efficacy and Safety of Sotagliflozin for People With Type 1 Diabetes and Chronic Kidney Disease Globe Newswire 4:05 PM
Lexicon Pharmaceuticals to Host Third Quarter 2024 Financial Results Conference Call and Webcast on November 12, 2024 Globe Newswire 8:00 AM

-- November 4, 2024 --

Lexicon to Present Preclinical IN VIVO Efficacy Data Demonstrating Ability of New Investigational Compound to Enhance and Maintain Semaglutide-Promoted Weight Loss Globe Newswire 8:00 AM

-- October 31, 2024 --

Lexicon Announces Outcome of FDA Advisory Committee for Zynquista (sotagliflozin) as an Adjunct to Insulin Therapy for Glycemic Control in Adults with Type 1 Diabetes and Chronic Kidney Disease Globe Newswire 6:54 PM

-- October 23, 2024 --

New Analysis of Phase 3 Data Demonstrating Renal Protective Benefits of Sotagliflozin to be Presented at ASN Kidney Week 2024 Globe Newswire 9:00 AM

-- October 22, 2024 --

Lexicon Announces Completion of Screening in Phase 2B Progress Study of LX9211 in Diabetic Peripheral Neuropathic Pain (DPNP) Globe Newswire 8:00 AM

-- October 16, 2024 --

Lexicon Announces Exclusive Licensing Agreement With Viatris for Sotagliflozin in All Markets Outside of the U.S. and Europe Globe Newswire 4:35 PM
Viatris Announces Exclusive Licensing Agreement with Lexicon Pharmaceuticals for Sotagliflozin in all Markets Outside of the U.S. and Europe PRNewswire 4:34 PM

-- September 27, 2024 --

Lexicon to Present Phase 3 Trial Design for Sotagliflozin in Hypertrophic Cardiomyopathy (HCM) at Upcoming Medical Congress Globe Newswire 8:00 AM

-- September 16, 2024 --

Lexicon Pharmaceuticals Announces Departure of President and Chief Operating Officer Globe Newswire 8:00 AM

-- September 10, 2024 --

New Secondary Analysis of Phase 3 Data Demonstrates Sotagliflozin Improves Time-In-Range (TIR) and Several Parameters of Glucose Control and Variability in Basal Insulin-Treated Type 2 Diabetes Globe Newswire 8:00 AM

-- September 3, 2024 --

Lexicon Pharmaceuticals to Participate in Upcoming September Investor Conferences Globe Newswire 4:00 PM
New Secondary Analysis of Phase 3 Data Demonstrates that INPEFA (Sotagliflozin) Benefited Heart Failure Patients Regardless of Diabetes Duration Globe Newswire 8:00 AM

-- August 21, 2024 --

Lexicon Pharmaceuticals Announces FDA Advisory Committee Meeting for Zynquista Globe Newswire 8:00 AM

-- August 13, 2024 --

Lexicon Pharmaceuticals Announces Strategic Repositioning to Drive Value and Growth of Commercial Portfolio Globe Newswire 8:30 AM

-- August 7, 2024 --

Efficacy and Safety Data of Sotagliflozin in Patients with Type 1 Diabetes and Chronic Kidney Disease Among Three Lexicon-Sponsored Presentations at the 2024 Annual Conference of the Association of Diabetes Care & Education Specialists Globe Newswire 8:00 AM

-- August 1, 2024 --

Lexicon Pharmaceuticals Reports Second Quarter 2024 Financial Results and Provides Business Update Globe Newswire 4:00 PM

-- July 25, 2024 --

Lexicon Pharmaceuticals to Host Second Quarter 2024 Financial Results Conference Call and Webcast on August 1, 2024 Globe Newswire 8:00 AM

-- July 16, 2024 --

Lexicon Pharmaceuticals Receives December 20, 2024 PDUFA Goal Date for Sotagliflozin Type 1 Diabetes NDA Resubmission Globe Newswire 8:00 AM

-- July 15, 2024 --

New Published Data Highlights Potential Cost-Savings of INPEFA (sotagliflozin) for Heart Failure Globe Newswire 8:00 AM

-- July 8, 2024 --

Lexicon Board of Directors Appoints Mike Exton, Ph.D. as New Chief Executive Officer and Director Globe Newswire 9:15 AM